title: TMC125: important one-year trial now recruiting in U.S.
abstract: An new NNRTI that greatly reduces HIV resistance to this major class of drugs is now recruiting at about 50 U.S. medical centers. It is active against virus resistant to efavirenz and nevirapine.
authors.forename: John S
authors.initials: JS
authors.lastname: James
mesh_terms: D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D009570:Nitriles; D011724:Pyridazines / Q000627:therapeutic use*; D011743:Pyrimidines; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D014481:United States
chemical_list: D009570:Nitriles; D011724:Pyridazines; D011743:Pyrimidines; D018894:Reverse Transcriptase Inhibitors; C451734:etravirine